Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Obesity By The Numbers

Executive Summary

Obesity is one of the most prevalent diseases in the US, according to CDC, which estimates that about one-third of Americans, or 76 million adults, are obese. Obesity leads to other chronic conditions like diabetes, heart disease and some cancers. Yet, patients and physicians have been slow to turn to drugs for treatment.

You may also be interested in...



Obesity Companies Prolong The Inevitable As Cash Runs Out

Arena and Vivus both announce efforts to conserve cash and they struggle with virtually nonexistent sales of their obesity drugs. Neither company has laid out plans for next steps.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Zafgen Drops Beloranib, But Its New Focus Raises Doubts

The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC065138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel